{"schema_version":"secwatch.filing_event.v1","accession":"0001386570-26-000017","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.963913+00:00","generated_at":"2026-05-15T09:35:53.117825+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Niagen Bioscience increases share repurchase authorization to $20M from $10M","bullets":["Board approved increase of share repurchase program from $10M to $20M.","Approximately $2.6M of common stock repurchased through March 17, 2026.","Program runs through October 31, 2027, unless modified or terminated.","CEO Rob Fried cited conviction in strategy and long-term value."],"urls":{"canonical":"https://secwatch.observer/filing/0001386570-26-000017","json":"https://secwatch.observer/filing/0001386570-26-000017.json","markdown":"https://secwatch.observer/filing/0001386570-26-000017.md","text":"https://secwatch.observer/filing/0001386570-26-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000138657026000017/0001386570-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000138657026000017/cdxc-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:35:53.117825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}